Lantheus’ (LNTH) “Neutral” Rating Reiterated at The Goldman Sachs Group

The Goldman Sachs Group reiterated their neutral rating on shares of Lantheus (NASDAQ:LNTH) in a research note released on Wednesday, MarketBeat reports. They currently have a $77.00 target price on the medical equipment provider’s stock, down from their previous target price of $110.00.

LNTH has been the subject of several other research reports. B. Riley cut their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. TD Cowen cut their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, September 15th. JMP Securities cut their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research note on Thursday, August 7th. Mizuho cut their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Finally, William Blair reiterated a “market perform” rating on shares of Lantheus in a research note on Wednesday, July 16th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $74.50.

Lantheus Price Performance

Shares of Lantheus stock opened at $53.54 on Wednesday. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. Lantheus has a twelve month low of $47.25 and a twelve month high of $118.21. The business has a 50-day moving average price of $54.50 and a 200 day moving average price of $74.73. The firm has a market cap of $3.64 billion, a PE ratio of 14.24 and a beta of 0.09.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million during the quarter. Sell-side analysts predict that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,812,000 shares of company stock worth $382,427,380 over the last quarter. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Silverberg Bernstein Capital Management LLC lifted its holdings in Lantheus by 8.1% in the third quarter. Silverberg Bernstein Capital Management LLC now owns 29,379 shares of the medical equipment provider’s stock valued at $1,507,000 after acquiring an additional 2,200 shares during the last quarter. Assenagon Asset Management S.A. acquired a new position in Lantheus in the third quarter valued at approximately $65,654,000. Moody National Bank Trust Division lifted its stake in Lantheus by 10.7% during the third quarter. Moody National Bank Trust Division now owns 16,716 shares of the medical equipment provider’s stock worth $857,000 after purchasing an additional 1,621 shares in the last quarter. Texas Permanent School Fund Corp lifted its stake in Lantheus by 12.5% during the second quarter. Texas Permanent School Fund Corp now owns 88,298 shares of the medical equipment provider’s stock worth $7,228,000 after purchasing an additional 9,801 shares in the last quarter. Finally, Osaic Holdings Inc. lifted its stake in Lantheus by 218.5% during the second quarter. Osaic Holdings Inc. now owns 23,177 shares of the medical equipment provider’s stock worth $2,026,000 after purchasing an additional 15,900 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.